VS41157

VS41157 is a preclinical-stage therapeutic candidate being developed by VeroScience for the treatment of pancreatic cancer. The drug utilizes VeroScience's proprietary Photo Immuno-Resetting Therapy (PIRT) technology, which involves the use of a photosensitizer—a tumor-localizing agent that remains non-toxic until it is irradiated by light of a specific wavelength. This mechanism is designed to elicit site-specific tumor cell death while sparing surrounding healthy tissues, thereby reducing the potential for systemic side effects. Preclinical studies in animal models have demonstrated the therapy's ability to target pancreatic tumors effectively without significant toxicity.